USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases
CLEVELAND, OH, UNITED STATES, January 8, 2024 /EINPresswire.com/ — NovelMed, a clinical-stage biopharmaceutical company with expertise in inflammatory and complement-related diseases, is pleased to announce that the United States Adopted Name (USAN) Council has officially assigned the generic name “Ruxoprubart (Ruk”soe proo’ bart)” to its monoclonal antibody candidate, NM8074, marking a significant milestone in the…
